8th Sep 2022 14:40
Arecor Therapeutics PLC - Essex, England-based biopharmaceutical company - Posts a widened pretax loss of GBP5.2 million in the six months to June 30, from GBP3.5 million a year earlier. Revenue, however, increases by 51% to GBP693,000 from GBP460,000, derived from "formulation development projects, in line with expectations". Research & Development costs soared to GBP4.8 million from GBP1.9 million a year earlier, Cash amounts to GBP13.7 million at June 30, compared to GBP22.1 million a year ago. Read More
